Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript

Summary by The Motley Fool
Wegovy pill uptake and CagriSema trial results shape the growth recovery story.

4 Articles

The Motley FoolThe Motley Fool
Lean Left

Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript

Wegovy pill uptake and CagriSema trial results shape the growth recovery story.

·Alexandria, United States
Read Full Article
wiwo.dewiwo.de

Wegovy: Novo Nordisk Makes a Profit Jump Thanks to Strong Demand for the Slimming Pill

The Wegovy reduction pill drives Novo Nordisk: Operating profit increases currency-adjusted by 27 percent.

·Düsseldorf, Germany
Read Full Article
privataaffarer.seprivataaffarer.se

Lower than Expected Results for Novo Nordisk

Danish pharmaceutical company Novo Nordisk reports an operating profit of 23,011 million Danish kroner for the third quarter of 2026.

Read Full Article
BizTocBizToc

Novo Nordisk Q3 sales at $11.9B, up 6%

Novo Nordisk A/S announced on Wednesday that its sales in the third quarter of fiscal 2026 totaled 79.2 billion Danish kroner (around $11.9 billion), up 6% from the same period in 2025.In the reported...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

BizToc broke the news on Wednesday, November 4, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Novo Nordisk icon

Novo Nordisk

Wegovy icon

Wegovy

Denmark icon

Denmark

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal